Quantification of [123I]FP-CIT SPECT brain images: An accurate technique for measurement of the specific binding ratio

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 33, Issue 12, 2006, Pages 1491-1499

  Tossici Bolt, Livia ^a   Hoffmann, Sandra M A ^a   Kemp, Paul M ^a   Mehta, Rajnikant L ^b   Fleming, John S ^a  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Brain SPECT; Dopamine transporters; Operator reproducibility; Quantification; Specific binding

Indexed keywords

CARBOMETHOXY 3BETA (4 IODOPHENYL)NORTROPANE I 123; DOPAMINE TRANSPORTER; TRACER; 2 CARBOMETHOXY 8 (3 FLUOROPROPYL) 3 (4 IODOPHENYL)TROPANE; 2-CARBOMETHOXY-8-(3-FLUOROPROPYL)-3-(4-IODOPHENYL)TROPANE; DIAGNOSTIC AGENT; RADIOACTIVE IODINE; TROPANE DERIVATIVE;

ADULT; AGED; ARTICLE; BINDING AFFINITY; BRAIN; CLINICAL ARTICLE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; FEMALE; HUMAN; IMAGE ANALYSIS; MALE; NEUROIMAGING; REPRODUCIBILITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STATISTICAL ANALYSIS; CHEMISTRY; CORPUS STRIATUM; METHODOLOGY; MIDDLE AGED; OBSERVER VARIATION; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; STANDARD; STATISTICS;

AGED; AGED, 80 AND OVER; BRAIN; CORPUS STRIATUM; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; OBSERVER VARIATION; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 33845350107     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-006-0155-x     Document Type: Article

References (38)

1. 123I-β-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm Suppl 1997;50:9-24
2. 123I]beta-CIT and SPECT in essential tremor and Parkinson's disease. J Neural Transm 1998;105:1213-1228
3. 123I]-FP- CIT study group. Mov Disord 2000;15:503-510
4. Ransmayr G, Seppi K, Donnemiller E, Luginger E, Marksteiner J, Riccabona G, et al. Striatal dopamine transporter function in dementia with Lewy bodies and Parkinson's disease. Eur J Nucl Med 2001;28:1523-1528
5. Walker Z, Costa DC, Walker RWH, Shaw K, Gacinovic S, Stevens T, et al. CLE differentiation of dementia with lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry 2002;73:130-140
6. O'Brien JT, Colloby S, Fenwick J, Williams ED, Firbank M, Burn D, et al. Dopamine transporter loss visualised with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 2004;61:919-925
7. 123I]beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 1996;46:231-237
8. 123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;62:133-140
9. 123I]FP-CIT SPECT in the demonstration of the dopaminergic deficit in Parkinson's disease. Eur J Nucl Med 1997;24:68-71
10. Seibyl JP, Marek K, Sheff K, Zoghbi S, Baldwin RB, Charney DS, et al. Iodine-123-β-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporter in healthy subjects and Parkinson's patients. J Nucl Med 1998;39:1500-1508
11. 99mTc]TRODAT-1 to dopamine transporters in patients with Parkinson's disease and in healthy volunteers. J Nucl Med 2000;41:584-589
12. 123I]IPT and single-photon emission tomography. Eur J Nucl Med 1997;24:415-421
13. 123I] β-CIT binding to dopamine transporter in healthy human subjects. J Cereb Blood Flow Metab 1994;14:982-994
14. 123I]FPCIT SPECT. J Nucl Med 1999;40:753-761
15. 99mTc] TRODAT-1 and single-photon emission tomography. Eur J Nucl Med 2000;27:1714-1718
16. Costa DC, Walker Z, Dizdarevic S, Ioannides C, Gacinovic S, Walker RW, et al. Striatal binding index of FP-CIT: a simple method to separate Parkinson's disease patients and controls [abstract]. Eur J Nucl Med 1998;25:1069
17. Bolt L, Fleming JS, Hoffmann SMA, Kemp PM, Costa DC. Quantifying DaTSCAN images: how automation reduces operator variability. Nucl Med Commun 2003;24:445
18. Fleming JS, Bolt L, Stratford JS, Kemp PM. The specific uptake size index for quantifying radiopharmaceutical uptake. Phys Med Biol 2004;49:N227-N234
19. Blinkov SM, Glezer II. The human brain in figures and tables. A quantitative handbook. New York: Basic Books, Plenum Press; 1968. pp 166-171
20. Aylward EH, Li Q, Habbak R, Warren A, Pulsifer MB, Barta PE, et al. Basal ganglia volume in adults with Down syndrome. Psychiatry Res Neuroimaging Section 1997;74:73-82
21. JL Fleiss. Statistical methods for rates and proportions. 2nd ed. New York: Wiley; 1981
22. Bland JM, Altman DG. Statistical method for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-310
23. Fleming JS, Alaamer AS. Influence of collimator characteristics on quantification in SPECT. J Nucl Med 1996;37:1832-1836
24. Hashimoto J, Sasaki T, Ogawa K, Kubo A, Motomura N, Ichihara T, et al. Effects of scatter and attenuation correction on quantitative analysis of β-CIT brain SPECT. Nucl Med Commun 1999;20:159-165
25. Kim KM, Varrone A, Watabe H, Shidahara M, Fujita M, Innis RB, et al. Contribution of scatter and attenuation compensation to SPECT images of nonuniformly distributed brain activities. J Nucl Med 2003;44:512-519
26. Parkinson Study Group. Dopamine transporter brain imaging to assess the effect of pramipexole vs levadopa on Parkinson disease progression. JAMA 2002;13:1653-1661
27. Kuikka JT, Bergstrom KA, Ahonen A, Hiltunen J, Haukka J, Länsimies E, et al. Comparison of iodine-123 labelled 2β-carbomethoxy-3β-(4- iodophenyl)tropane and 2β-carbometho xy-3β-(4-iodophenyl)-N-(3- fluoropropyl)nortropane for imaging the dopamine transporter in the living human brain. Eur J Nucl Med 1995;22:356-360
28. Booij J, Habraken JBA, Bergmans P, Tissingh G, Winogrodzka A, Wolters EC, et al. Imaging of dopamine transporter with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease. J Nucl Med 1998;39:1879-1884
29. 2 receptor binding with iodine-123-iodobenzofuran SPECT. J Nucl Med 1998;39:1511-1518
30. 123I]IPT binding to presynaptic dopamine transporter: variation of intra- and interobserver data evaluation in parkinsonian patients and controls. Eur J Nucl Med 2000;27:1809-1812
31. Cot A, Falcón C, Crespo C, Sempau J, Pareto D, Bullich S, et al. Absolute quantification of dopaminergic neurotransmission SPECT using a Monte Carlo-based scatter correction and fully 3-dimensional reconstruction. J Nucl Med 2005;46:1497-1504
32. 123I]-β-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov Disord 2000;15:1158-1167
33. 123I-beta-CIT SPECT: binding kinetics and effects of normal aging. J Nucl Med 2000;41:36-44
34. van Dyck CH, Seibyl JP, Malison RT, Laurelle M, Wallace E, Zoghbi SS, et al. Age-related decline in striatal dopamine transporter binding with iodine-123-β-CIT SPECT. J Nucl Med 1995;36:1175-1181
35. Schwarz J, Storch A, Koch W, Pogarelli O, Radau PE, Tatsch K. Loss of dopamine transporter binding follows a single exponential rather than linear decline. J Nucl Med 2004;45:1694-1697
36. 123I-FPCIT SPECT in normal control and Parkinson's disease patients. Ann Nucl Med 2004;18:609-616
37. Seibyl JP, Laurelle M, van Dick CH, Wallace E, Baldwin RM, Zoghbi S, et al. Reproducibility of iodine-123-β-CIT SPECT brain measurement of dopamine transporters. J Nucl Med 1996;37:222-228
38. 123I-FP-CIT SPECT: comparability of modern SPECT systems. J Nucl Med 2003;45:839-845